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Background/Introduction
HTK-Solution (Custodiol) is a well-established cardio-
plegic and organ preservation solution. We currently
developed a novel HTK based solution Custodiol-N
which includes iron chelators to reduce oxidative injury
as well as L-arginine, to improve endothelial function.
Aims/Objectives
In the present first-in-human study, Custodiol-N was
compared with Custodiol in patients undergoing elective
coronary bypass surgery.
Method
The study was designed as prospective randomized dou-
ble blind non-inferiority trial. Primary end-point was
area under the curve (AUC) of creatine kinase MB
(CKMB) within the first 24 hours after surgery. Second-
ary endpoints included, peak CKMB and troponin-T
and AUC of troponin-T release, cardiac index, cumula-
tive catecholamine dose, ICU-stay and mortality. All
values are given as mean ± SD, p < 0.05 was considered
as statistically significant.
Results
Early termination of the trial was performed per protocol
as the primary non-inferiority end point was reached after
inclusion of 101 patients. Patient characteristics, medical
history, operation and cross-clamp times did not differ
between the groups. CKMB AUC (878 ± 549 vs. 778 ±
439 h*U/l, non-inferiority p < 0.001) and Troponin-T
AUC (12990 ± 8347 vs. 13498 ± 6513 h*pg/ml, non-
inferiority p < 0.001) was similar in both groups.
Although the trial was designed for non-inferiority, peak
CKMB (52 ± 40 vs. 41 ± 30 U/l, superiority p < 0.002)
was significantly lower in the Custodiol-N group. Cardiac
index, catecholamines ICU-stay and mortality (1 death in
the control group) was similar in both groups.
Discussion/Conclusion
This study shows that Custodiol-N is safe and provides
similar cardiac protection as the established HTK-
Custodiol solution. The significantly reduced peak
CKMB levels in the Custodiol-N group may implicate a
beneficial effect on ischemia/reperfusion injury in the
setting of coronary bypass surgery.
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